Published in J Exp Med on October 03, 2005
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007) 2.68
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity (2009) 2.64
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
T cell immune reconstitution following lymphodepletion. Semin Immunol (2007) 2.35
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 2.13
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res (2010) 1.92
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood (2012) 1.90
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol (2009) 1.89
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood (2016) 1.72
Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70
Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood (2010) 1.66
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood (2015) 1.57
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood (2008) 1.52
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood (2009) 1.51
CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A (2008) 1.48
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother (2012) 1.47
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol (2013) 1.46
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol (2006) 1.43
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol (2016) 1.39
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther (2008) 1.38
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther (2009) 1.35
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A (2009) 1.34
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther (2009) 1.29
Radiation-induced effects and the immune system in cancer. Front Oncol (2012) 1.27
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.26
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res (2013) 1.22
Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol (2012) 1.20
Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol (2012) 1.20
Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother (2008) 1.18
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Immunotherapy for ovarian cancer: what's next? J Clin Oncol (2010) 1.17
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 1.16
Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A (2008) 1.16
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood (2009) 1.15
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood (2006) 1.14
CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res (2009) 1.14
Cancer immunotherapy. Mol Oncol (2012) 1.13
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res (2011) 1.13
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol (2000) 12.81
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med (2002) 7.11
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med (2002) 5.64
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med (2002) 5.09
Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med (2000) 5.07
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med (2000) 4.54
Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol (2004) 4.35
Cutting edge: naive T cells masquerading as memory cells. J Immunol (2000) 4.27
T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 4.16
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 3.41
Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med (2002) 3.20
In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med (2003) 2.59
Autologous regulation of naive T cell homeostasis within the T cell compartment. J Immunol (2001) 2.52
Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med (2003) 2.51
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol (1975) 2.06
Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med (2004) 1.17
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol (2003) 15.51
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med (2002) 7.11
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06